Dimitris Moulavasilis – Group CEO, M42
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
GSK GCC & Levant
GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
For information about the company’s products or career opportunities, please contact htem at their local offices.
Sheikh Zayed Rd
PO Box 50199
Dubai, UAE
Phone: +9714 403 7100
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
In less than a decade, the Abu Dhabi Stem Cells Center has emerged as a central pillar in the UAE’s ambition to build a fully integrated ecosystem for advanced therapies.…
Global advances in rare blood disorders increasingly hinge on where evidence is generated, how patients are followed, and whether innovation reaches beyond a limited few. Khaled Musallam describes how clinical…
CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has…
Rare diseases remain among the most complex and least visible challenges facing healthcare systems, particularly in regions where genetic factors amplify the burden. In this conversation, Ahmed Salem, Head of…
As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin…
Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional…
Hussein Abhari, Head of the MENA region, QIAGEN, has led the company’s regional presence since 2017, spanning products for molecular research and clinical testing. His priorities focus on strengthening long-term…
Dr Rania Alshami reflects on two decades in the Middle East and North Africa clinical research ecosystem, charting the region’s regulatory maturation, rare disease opportunities, and growing role in early-phase…
As global pharmaceutical strategies continue to shift, Ali Sleiman reflects on how Genesys Pharmaceuticals is being built as a disciplined execution platform for the Middle East and Africa. The interview…
Rare diseases in the Middle East and Africa are no longer an afterthought. As regulatory frameworks mature and governments demand deeper partnership, access, science and local commitment are being redefined.…
See our Cookie Privacy Policy Here
